Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661022 · ClinicalTrials.gov registry record · Phase 1
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Stemline Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02661022: Clinical Trial Phase 1 study, sponsored by Stemline Therapeutics.
NCT02661022 is a Phase 1 study that was terminated before completion, run by Stemline Therapeutics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661022, a Phase 1 study, was terminated before completion, sponsored by Stemline Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
Primary Outcome
To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma
Interventions
- DRUG SL-401 7 µg/kg/day
- DRUG SL-401 9 µg/kg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Why NCT02661022 stopped before completion
NCT02661022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which SL-401 7 µg/kg/day is the first listed.
NCT02661022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02661022 about?
NCT02661022 is a clinical study titled "SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma". A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
What is the current status of trial NCT02661022?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02661022?
The interventions under investigation include: SL-401 7 µg/kg/day (DRUG), SL-401 9 µg/kg/day (DRUG).
Who is sponsoring clinical trial NCT02661022?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02661022's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia